Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine


Author index

Page Path
HOME > Articles and issues > Author index
Sanghoon Jheon 2 Articles
Loss of PTEN Expression is an Independent Poor Prognostic Factor in Non-small Cell Lung Cancer.
Seol Bong Yoo, Xianhua Xu, Hyun Ju Lee, Sanghoon Jheon, Choon Taek Lee, Gheeyoung Choe, Jin Haeng Chung
Korean J Pathol. 2011;45(4):329-335.
  • 3,877 View
  • 29 Download
  • 8 Citations
AbstractAbstract PDF
Alterations in the phosphatase and tensin homolog (PTEN) are correlated with tumor progression. Downregulation of PTEN is related to drug resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the prognostic significance of PTEN in patients with NSCLC and its correlation with EGFR.
Two hundred eighty eight surgically resected NSCLC samples, including 168 adenocarcinomas (ADCs), 99 squamous cell carcinomas (SCCs) and 21 other NSCLCs were analyzed for the PTEN. The results were correlated with other clinicopathological variables including EGFR amplification and mutation.
Loss of PTEN was detected in 42.4% of NSCLCs, specifically 28.6% of ADCs, 66.7% of SCCs, and 38.1% of others. Loss of PTEN was significantly associated with SCC, smoking, male gender, and higher stage. In a multivariate analysis, loss of PTEN was significantly associated with short progression-free survival (p=0.037). No association between PTEN and EGFR was observed.
These results suggest that loss of PTEN results in shorter progression-free survival in patients with NSCLC, and loss of PTEN is more associated with SCC, smoking, male gender, and higher T stage by the 7th tumor, node and metastasis staging system but not EGFR status.


Citations to this article as recorded by  
  • Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations
    Philippe Jamme, Marie Fernandes, Marie-Christine Copin, Clotilde Descarpentries, Fabienne Escande, Angela Morabito, Valérie Grégoire, Matthieu Jamme, Simon Baldacci, David Tulasne, Zoulika Kherrouche, Alexis B. Cortot
    Journal of Thoracic Oncology.2020; 15(5): 741.     CrossRef
  • PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
    Francesca Luongo, Francesca Colonna, Federica Calapà, Sara Vitale, Micol E. Fiori, Ruggero De Maria
    Cancers.2019; 11(8): 1076.     CrossRef
  • PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
    Anastasios Gkountakos, Giulia Sartori, Italia Falcone, Geny Piro, Ludovica Ciuffreda, Carmine Carbone, Giampaolo Tortora, Aldo Scarpa, Emilio Bria, Michele Milella, Rafael Rosell, Vincenzo Corbo, Sara Pilotto
    Cancers.2019; 11(8): 1141.     CrossRef
  • PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature
    Jian Xiao, Cheng-Ping Hu, Bi-Xiu He, Xi Chen, Xiao-Xiao Lu, Ming-Xuan Xie, Wei Li, Shu-Ya He, Shao-Jin You, Qiong Chen
    Oncotarget.2016; 7(36): 57832.     CrossRef
  • Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment
    Seol Bong Yoo, Yu Jung Kim, Hyojin Kim, Yan Jin, Ping-Li Sun, Sanghoon Jheon, Jong Seok Lee, Jin-Haeng Chung
    Annals of Surgical Oncology.2013; 20(S3): 545.     CrossRef
  • High concordance ofEGFRmutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas
    Ping-Li Sun, Yan Jin, Hyojin Kim, Choon-Taek Lee, Sanghoon Jheon, Jin-Haeng Chung
    Cancer Cytopathology.2013; 121(6): 311.     CrossRef
  • Impact of HER2 and PTEN Simultaneous Deregulation in Non-small Cell Lung Carcinoma: Correlation with Biological Behavior
    Ioannis Panagiotou, Stavros N. Georgiannos, Evangelos Tsiambas, Andreas Karameris, Marios Konstantinou, Andreas C. Lazaris, Nikolaos Kavantzas, George Vilaras, Efstratios Patsouris
    Asian Pacific Journal of Cancer Prevention.2012; 13(12): 6311.     CrossRef
  • Expression of the Mammalian Target of Rapamycin Pathway Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma
    Hyun-Soo Kim, Gou Young Kim, Sung-Jig Lim, Youn Wha Kim
    Pathobiology.2012; 79(2): 84.     CrossRef
ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC.
Han Suk Ryu, Xianhua Xu, Hyojin Kim, Jong Suk Lee, Sanghoon Jheon, Jin Haeng Chung
Korean J Pathol. 2011;45(1):45-52.
  • 2,338 View
  • 14 Download
AbstractAbstract PDF
The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its significance for adjuvant chemotherapy.
The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146).
Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001).
These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.

JPTM : Journal of Pathology and Translational Medicine